

ORDER SHEET

Kimyrsa™
(oritavancin) for injection
1,200 mg

Order through your distributor or our
CorMedix Direct program today



Not Actual Size

NDC No.	70842-225-01
How supplied	KIMYRSA® is supplied as a sterile white to off-white or pink lyophilized powder in single-dose clear glass vials containing 1,200 mg of oritavancin. One vial is packaged in a carton to supply a single 1,200 mg dose treatment.
Storage and handling	KIMYRSA® vials should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Carton size	1.7717 x 1.7717 x 3.0709 in (DxWxH)
Carton weight	0.10 lb/45.36 g

KIMYRSA® is available through the following distributors:

Distributor	Phone	Email	Distributor Item #
AmerisourceBergen Specialty Distribution (ASD)	800-746-6273	service@asdhealthcare.com	10307207
Besse Medical	800-543-2111	service@besse.com	10259422
Cardinal Specialty Pharmaceutical Distribution (CAH SPD)	855-855-0708	GMB-SPD-CSORDERENTRY@cardinalhealth.com	5728753
CuraScript SD	877-599-7748	customer.service@curascript.com	462713
McKesson Plasma & Biologics	877-625-2566	mpborders@mckesson.com	3084241
McKesson Specialty Health	855-477-9800	mshcustomercare-mspl@mckesson.com	5022158
Morris & Dickson Specialty Distribution	800-388-3833	customerservice@morrisdickson.com	083700

For questions or product availability, please contact your distributor. For additional assistance, please contact us at cormedixtrade@cormedix.com.

Please see next page for Indications and Usage, Important Safety Information, and full Prescribing Information.

INDICATIONS AND USAGE

KIMYRSA® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following Gram-positive microorganisms: *Staphylococcus aureus* (including methicillin-susceptible [MSSA] and methicillin-resistant [MRSA] isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus anginosus* group (includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), and *Enterococcus faecalis* (vancomycin-susceptible isolates only).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of KIMYRSA® and other antibacterial drugs, KIMYRSA® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

Contraindications

Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA® administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for approximately 120 hours (5 days) after KIMYRSA® administration.

KIMYRSA® is contraindicated in patients with known hypersensitivity to oritavancin products.

Warnings and Precautions

Coagulation test interference: Oritavancin has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours and ACT for up to 24 hours. Oritavancin has also been shown to elevate D-dimer concentrations up to 72 hours. For patients who require aPTT monitoring within 120 hours of KIMYRSA® dosing, consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of oritavancin products including KIMYRSA®. Discontinue infusion if signs of acute hypersensitivity occur. Closely monitor patients with known hypersensitivity to glycopeptides.

Infusion Related Reactions: Infusion reactions characterized by chest pain, back pain, chills and tremor have been observed with the use of oritavancin products (e.g. KIMYRSA®), including after the administration of more than one dose of oritavancin during a single course of therapy. Stopping or slowing the infusion may result in cessation of these reactions.

Clostridioides difficile-associated diarrhea: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: Oritavancin has been shown to artificially prolong PT/INR for up to 12 hours. Patients should be monitored for bleeding if concomitantly receiving KIMYRSA® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing KIMYRSA® in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions ($\geq 3\%$) in patients treated with oritavancin products were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea. The adverse reactions occurring in ≥ 2 patients receiving KIMYRSA® were hypersensitivity, pruritus, chills and pyrexia.

Please see full [Prescribing Information](#).

Medical Information

For Medical Information, please call 1-844-633-6568. You are encouraged to report side effects or product complaints associated with KIMYRSA®.

 1-844-633-6568

 medinfo@cormedix.com



KIMYRSA® is a registered trademark of Melinta Therapeutics LLC, generally known as CorMedix Therapeutics.
© 2026 Melinta Therapeutics, LLC. All rights reserved. US-KIM-0362 03/2026

Kimyrsa[™]
(oritavancin) for injection
1,200 mg